论文部分内容阅读
目的:观察肥胖症患者应用奥利司他减轻体重治疗对血清瘦素水平的影响。方法:60例肥胖症患者入选为期24周的随机双盲研究,分为奥利司他组39例和安慰剂组20例,在轻度低热卡饮食及增加有氧运动的基础上,分别服奥利司他120mg或安慰剂1片,每日3次,观察体重及血清瘦素水平的改变。结果:经治疗24周,奥利司他组的体重由(79.3±1.8)kg降为(72.9±1.8)kg,安慰剂组相应为(80.6±2.6)kg、(79.0±2.9)kg,奥利司他组较安慰剂组疗效明显(P<0.01)。瘦素水平与体重指数呈正相关(r=0.59,P<0.05),而与治疗方法无关。结论:奥利司他可作为减轻体重的辅助药物,并通过减轻体重降低血清瘦素水平。
Objective: To observe the effect of orlistat treatment on the level of serum leptin in obesity patients. Methods: Sixty obese patients were enrolled in a randomized, double-blind, 24-week study of 39 patients with orlistat and 20 with placebo. On the basis of mild hypocaloric diet and increased aerobic exercise, Orlistat 120mg or placebo 1, 3 times a day to observe the body weight and serum leptin levels change. RESULTS: At 24 weeks of treatment, body weight in the orlistat group was reduced from (79.3 ± 1.8) kg to (72.9 ± 1.8) kg vs (80.6 ± 2.6) kg and (79.0 ± 2.9) kg in the placebo group The effect of paclitaxel group was better than that of placebo group (P <0.01). Leptin level was positively correlated with body mass index (r = 0.59, P <0.05), but not with the treatment. CONCLUSIONS: Orlistat can be used as a weight-reducing adjunct and to reduce serum leptin levels by reducing body weight.